Skip to Main Content

WASHINGTON – Lawmakers are facing off over the future of the Food and Drug Administration’s so-called accelerated approval pathway, with Biogen’s controversial Alzheimer’s drug Aduhelm front and center in the debate.

The very first minutes of a Thursday hearing, originally billed as an opportunity to highlight roughly 20 different health policy measures, focused on the future of accelerated approval, which allows the FDA to approve drugs without clear evidence they prolong patients’ lives.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment